10X Genomics Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? 10X Genomics Inc trades at $47.2 (market cap $5.48B), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.95. The key difference: 10X Genomics Inc is trading nearer its 52-week high, Vanguard S&P 500 Growth Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| TXG | VOOG | |
|---|---|---|
Market Cap | $5.48B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $45.80 | $85.11 |
52-Week Low | $11.34 | $65.32 |
Enterprise Value | $5.02B | — |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →